PRINT OUT

Leading Products


Feb 5. 2020
(Â¥ million)

Brand name Active Ingredient Indications Launch
Date 		Sales
2017 		Sales
2018 		Sales 2019
Apr.-Dec. Annual
(estimated)
Vidaza azacitidine myelodysplastic syndrome Mar-2011 15,643 14,453 12,165 15,400
Zalutia tadalafil urinary disorder caused by benign prostatic hyperplasia Apr-2014 10,449 12,118 10,297 13,000
Tramal, Onetram tramadol hydrochloride cancer pain, chronic pain Sep-2010 6,622 7,196 5,636 7,100
Uptravi selexipag pulmonary arterial hypertension Nov-2016 2,690 4,825 4,753 7,300
Adcirca tadalafil pulmonary arterial hypertension Dec-2009 4,617 5,173 4,242 5,400
Cialis tadalafil erectile dysfunction Jul-2009 3,825 4,592 3,525 3,900
Gazyva obinutuzumab CD20-positive follicular lymphoma Aug-2018 - 1,417 3,386 4,200
Lunabell norethisterone and ethinylestradiol dysmenorrhea Jul-2008 5,374 4,658 1,729 1,900
Azunol Gargle sodium gualenate pharyngitis, tonsillitis, stomatitis, etc. Aug-2002 2,363 2,169 1,657 2,050
Eviprostat herbal extracts benign prostatic hyperplasia Apr-1967 2,761 2,137 1,390 1,700
Erizas dexamethasone cipecilate allergic rhinitis Dec-2009 2,916 2,987 1,109 2,700
Profit in co-promotion 3,962 5,057 4,438 6,000
Revenues from the licensing of industrial 10,378 16,621 11,197 16,400
Pharmaceuticals 87,416 100,223 76,665 101,100
Functional Food 14,031 14,492 11,448 14,900
Net Sales 101,448 114,716 88,113 116,000

Japanese page

Financial Information

page-top
Copyright © 2008-2020 by NIPPON SHINYAKU CO.,LTD. All rights reserved.